KR20020025217A - 토르세미드 동질이상 - Google Patents

토르세미드 동질이상 Download PDF

Info

Publication number
KR20020025217A
KR20020025217A KR1020027001867A KR20027001867A KR20020025217A KR 20020025217 A KR20020025217 A KR 20020025217A KR 1020027001867 A KR1020027001867 A KR 1020027001867A KR 20027001867 A KR20027001867 A KR 20027001867A KR 20020025217 A KR20020025217 A KR 20020025217A
Authority
KR
South Korea
Prior art keywords
torsemide
variant
solvent
mixture
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020027001867A
Other languages
English (en)
Korean (ko)
Inventor
아로니메주디스
레오노브데이비드
코르도바마르코
슈와쯔안첼
돌리츠키벤-지온
Original Assignee
추후보정
테바 파마슈티컬 인더스트리즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 추후보정, 테바 파마슈티컬 인더스트리즈 리미티드 filed Critical 추후보정
Publication of KR20020025217A publication Critical patent/KR20020025217A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Details Of Garments (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)
KR1020027001867A 1999-08-11 2000-08-11 토르세미드 동질이상 Ceased KR20020025217A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US14830599P 1999-08-11 1999-08-11
US60/148,305 1999-08-11
US18312700P 2000-02-17 2000-02-17
US60/183,127 2000-02-17
US21527300P 2000-06-30 2000-06-30
US60/215,273 2000-06-30
PCT/US2000/022081 WO2001010441A1 (en) 1999-08-11 2000-08-11 Torsemide polymorphs

Publications (1)

Publication Number Publication Date
KR20020025217A true KR20020025217A (ko) 2002-04-03

Family

ID=27386674

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027001867A Ceased KR20020025217A (ko) 1999-08-11 2000-08-11 토르세미드 동질이상

Country Status (24)

Country Link
US (1) US6465496B1 (enExample)
EP (1) EP1207880A4 (enExample)
JP (1) JP2003527319A (enExample)
KR (1) KR20020025217A (enExample)
CN (1) CN1378448A (enExample)
AU (1) AU781461C (enExample)
BG (1) BG106400A (enExample)
CA (1) CA2379322A1 (enExample)
CZ (1) CZ2002404A3 (enExample)
DE (1) DE00957398T1 (enExample)
ES (1) ES2204354T1 (enExample)
HK (1) HK1046636A1 (enExample)
HR (1) HRP20020120A2 (enExample)
HU (1) HUP0204318A3 (enExample)
IL (1) IL148031A0 (enExample)
LT (1) LT5004B (enExample)
MX (1) MXPA02001369A (enExample)
NO (1) NO20020622L (enExample)
PL (1) PL354262A1 (enExample)
SI (1) SI20816A (enExample)
SK (1) SK1912002A3 (enExample)
TR (1) TR200200353T2 (enExample)
WO (1) WO2001010441A1 (enExample)
YU (1) YU9502A (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100845383B1 (ko) * 2004-12-24 2008-07-09 일동제약주식회사 토르세미드 변형체(ⅰ)의 제조방법

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482417B2 (en) * 2000-02-17 2002-11-19 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulation comprising torsemide modification II
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
HRP20000162B1 (en) 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
US7067700B2 (en) 2001-05-31 2006-06-27 Fermion Oy Process for preparing sertraline hydrochloride polymorphic form II
IN192178B (enExample) 2001-08-03 2004-03-06 Ranbaxy Lab
US20030119882A1 (en) * 2001-10-22 2003-06-26 Markus Maegerlein Solid pharmaceutical composition containing torasemide
ITMI20020639A1 (it) * 2002-03-27 2003-09-29 Cosma S P A Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea
HRP20020603B1 (en) * 2002-07-19 2008-11-30 Pliva D.D. New process for the preparation of modification i n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide
CA2424644A1 (en) * 2003-04-07 2004-10-07 David John Mckenzie Preparation of torasemide
ES2244324B1 (es) * 2004-03-25 2006-11-16 Ferrer Internacional, S.A. Composiciones diureticas de liberacion prolongada.
AT500576B1 (de) * 2004-07-28 2006-11-15 Sanochemia Pharmazeutika Ag Verfahren zur reindarstellung von kristallformen von torsemid
US20070122483A1 (en) * 2005-11-29 2007-05-31 Sharon Myers Fluocinolone acetonide drug substance polymorphic interconversion
SG10202012791TA (en) 2013-11-15 2021-01-28 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
CN105949115A (zh) * 2016-05-26 2016-09-21 南京正科医药股份有限公司 一种新晶型托拉塞米
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法
CN117486789A (zh) * 2023-12-29 2024-02-02 江西中医药大学 一种托拉塞米共晶盐及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34672A (en) 1862-03-18 Improved convertible boat, bridge, and tent
US30633A (en) 1860-11-13 Improvement in fire-escapes
US4055650A (en) * 1974-04-17 1977-10-25 A. Christiaens Societe Anonyme Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines
GB1477664A (en) 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
DE3529529A1 (de) 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
DE3623620A1 (de) 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
HRP980532B1 (en) * 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US5914336A (en) 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
US6166045A (en) * 1998-06-02 2000-12-26 Roche Diagnostics Gmbh Torasemide of modification III
HRP20000162B1 (en) * 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
US6635765B2 (en) * 2000-03-20 2003-10-21 Teva Pharmaceutical Industries, Ltd. Processes for preparing torsemide intermediate
HRP20000328A2 (en) * 2000-05-19 2002-02-28 Pliva Farmaceutska Ind Dionik Novel polymorph v of torasemide

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100845383B1 (ko) * 2004-12-24 2008-07-09 일동제약주식회사 토르세미드 변형체(ⅰ)의 제조방법

Also Published As

Publication number Publication date
CN1378448A (zh) 2002-11-06
HRP20020120A2 (en) 2003-10-31
NO20020622L (no) 2002-03-14
PL354262A1 (en) 2003-12-29
SI20816A (sl) 2002-08-31
EP1207880A4 (en) 2004-09-01
WO2001010441A1 (en) 2001-02-15
DE00957398T1 (de) 2004-04-15
LT5004B (lt) 2003-03-25
HK1046636A1 (zh) 2003-01-24
EP1207880A1 (en) 2002-05-29
YU9502A (sh) 2005-06-10
JP2003527319A (ja) 2003-09-16
CZ2002404A3 (cs) 2002-06-12
TR200200353T2 (tr) 2002-06-21
NO20020622D0 (no) 2002-02-08
HUP0204318A3 (en) 2005-03-29
HUP0204318A2 (en) 2003-05-28
BG106400A (en) 2002-08-30
MXPA02001369A (es) 2005-08-26
AU6902600A (en) 2001-03-05
US6465496B1 (en) 2002-10-15
CA2379322A1 (en) 2001-02-15
AU781461C (en) 2006-02-23
LT2002017A (en) 2002-11-25
SK1912002A3 (en) 2002-07-02
ES2204354T1 (es) 2004-05-01
IL148031A0 (en) 2002-09-12
AU781461B2 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
KR20020025217A (ko) 토르세미드 동질이상
CN115368423B (zh) 还原型β-烟酰胺单核苷酸二钠盐的多晶型及其制法和用途
EP4153588A1 (en) Solid state forms of amg-510 and process for preparation thereof
JP2006137778A (ja) ゾルピデムヘミタートレイト
ZA200407799B (en) Lansoprazole polymorphs and processes for preparation thereof
KR20040036932A (ko) 발라사이클로비르 염산염의 결정질 형태
WO2020181025A1 (en) Solid state forms of baloxavir marboxil
EA014164B1 (ru) Новая кристаллическая форма производного пиридазино[4,5-в]индола
CN114026085A (zh) (e)-3-[2-(2-噻吩基)乙烯基]-1h-吡唑的固体形式
RU2228931C2 (ru) Кристаллические формы 3-(2,4-дихлорбензил)-2-метил-n-(пентилсульфонил)-3h- бензимидазол-5-карбоксамида
HUP0302135A2 (hu) A toraszemid új V. polimorf módosulata, eljárás előállítására, alkalmazása nyersanyagként, valamint ilyen módosulatot tartalmazó gyógyászati készítmények
US20070260068A1 (en) Method for the Preparation of Crystal Forms of Torsemide in a Pure State
CN115073384B (zh) 一种阿昔莫司晶型及其制备方法
KR20080086937A (ko) 나테글리나이드의 다형태
KR102111247B1 (ko) 다파글리플로진 무정형 형태의 공결정 또는 복합제
ZA200200967B (en) Tomsemide Polymorphs.
EP1713769B1 (en) Amorphous tamsulosin hydrochloride
KR20230087557A (ko) 로레시비빈트의 고상형
US20040138469A1 (en) Process for the synthesis of torsemide, in particular of pure and stable form II
KR20080106232A (ko) 베시피르딘 클로하이드레이트의 결정형, 그 제조 방법 및 용도
EP1655285A1 (en) Method for preparation of a crystalline form of carvedilol (form II)
WO2004076406A2 (en) Losartan potassium polymorphs and process for the preparation thereof
HK1033669A (en) An improved method of synthesis for 6,9-bis[(2-aminoethyl)amino]benzo[g] isoquinoline-5,10-dione and its dimaleate salt
MX2007008509A (es) Forma cristalina 2 de n-((2z)-2-((4-hidroxifenil)imino)-1,2- dihidro-3-piridinil)-4-metoxibencenosulfonamida.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000